TRIB2 and chronic myelogenous leukemia, BCR-ABL1 positive: Reports demonstrate that TRIB2 knockdown can limit tumor growth and proliferation and limit drug resistance in patients suffering from human chronic myelogenous leukemia (CML), mainly through the ERK/STAT3 pathway.